Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on Race

被引:5
|
作者
Zimmerman, Raquel [1 ,2 ]
Bilen, Mehmet A. [3 ,4 ]
Heath, Elisabeth, I [3 ]
Nandagopal, Lakshminarayanan [5 ]
Swami, Umang [6 ]
Kessel, Adam [6 ]
Jaeger, Ellen [7 ]
Wesolowski, Sergiusz [2 ]
Hernanadez, Edgar J. [2 ]
Chipman, Jonathan [1 ]
Mack, Alleda [8 ]
Ravindranathan, Deepak [3 ]
Maughan, Benjamin L. [1 ]
Nussenzveig, Roberto [6 ]
Yandell, Mark [2 ]
Kohli, Manish [6 ]
Lilly, Michael B. [9 ]
Sartor, A. Oliver [7 ]
Agarwal, Neeraj [6 ]
Barata, Pedro C. [7 ]
机构
[1] Univ Utah, Sch Med, Salt Lake City, UT USA
[2] Univ Utah, Dept Human Genet, Salt Lake City, UT USA
[3] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA USA
[4] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[5] Univ Alabama Birmingham, Birmingham, AL USA
[6] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA
[7] Tulane Univ, Med Sch, Sect Hematol Oncol, Deming Dept Med, New Orleans, LA 70118 USA
[8] Wayne State Univ, Sch Med, Dept Oncol, Karmanos Canc Inst, Detroit, MI USA
[9] Med Univ South Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA
来源
ONCOLOGIST | 2022年 / 27卷 / 10期
关键词
prostate cancer; Black; White; cell-free DNA; comprehensive genomic profiling;
D O I
10.1093/oncolo/oyac176
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This article compares the cell-free DNA (cfDNA) genomic landscape of men with advanced prostate cancer with a focus on differences based on race. Advanced prostate cancer (aPC) in Black men was reported to present with aggressive features and to be associated with poor prognosis. Herein, we compared the cell-free DNA (cfDNA) genomic landscape of aPC in Black vs White men. Patients (pts) with aPC from 6 academic institutions and available cfDNA comprehensive genomic profiling (CGP) were included. Association between mutated genes and race was evaluated using Barnard's test and a Probabilistic Graphical Model (PGM) machine learning approach. Analysis included 743 aPC pts (217 Black, 526 White) with available cfDNA CGP. The frequency of alterations in the androgen receptor gene was significantly higher in Black vs White men (55.3% vs 35% respectively, P < .001). Additionally, alterations in EGFR, MYC, FGFR1, and CTNNB1 were present at higher frequencies in Black men. PGM analysis and Barnard's test were concordant. Findings from the largest cohort of Black men with aPC undergoing cfDNA CGP may guide further drug development in these men.
引用
收藏
页码:E815 / E818
页数:4
相关论文
共 50 条
  • [31] Genomic and fragmentomic landscapes of cell-free DNA for early cancer detection
    Bruhm, Daniel C.
    Vulpescu, Nicholas A.
    Foda, Zachariah H.
    Phallen, Jillian
    Scharpf, Robert B.
    Velculescu, Victor E.
    NATURE REVIEWS CANCER, 2025, : 341 - 358
  • [32] Transcriptomic profiling and genomic rearrangement landscape of Nigerian prostate cancer
    Mavura, Yusuph
    Song, Hanbing
    Xie, Jamie
    Tamayo, Pablo
    Mohammed, Abdullahi
    Lawal, Ahmad T.
    Bello, Ahmad
    Ibrahim, Sani
    Faruk, Mohammed
    Huang, Franklin W.
    PROSTATE, 2023, 83 (05): : 395 - 402
  • [33] Re: Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2017, 197 (03): : 698 - 698
  • [34] Comprehensive genomic profiling (CGP) utilizing cell-free DNA (cfDNA) in patients (pts) with pancreatic ductal adenocarcinoma (PDAC).
    George, Ben
    Haberberger, James
    Ferguson, Naomi L.
    Gjoerup, Ole
    McGregor, Kimberly
    Hendifar, Andrew Eugene
    Laheru, Daniel A.
    Weekes, Colin D.
    Ross, Jeffrey S.
    Hemmerich, Amanda
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [35] Analytical Validation of the Labcorp Plasma Complete Test, a Cell-Free DNA Comprehensive Genomic Profiling Tool for Precision Oncology
    Verner, Ellen L.
    Jackson, Jennifer B.
    Maddox, Cynthia
    Valkenburg, Kenneth C.
    White, James R.
    Occean, James
    Morris, Laine
    Karandikar, Aanavi
    Gerding, Kelly M. R.
    Sausen, Mark
    Koohestani, Faezeh
    Severson, Eric A.
    Jensen, Taylor J.
    Caveney, Brian J.
    Eisenberg, Marcia
    Ramkissoon, Shakti H.
    Greer, Amy E.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2025, 27 (03): : 216 - 231
  • [36] Differences in the genomic profiles of cell-free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC
    Wu, Zhen
    Yang, Zhen
    Li, Chun Sun
    Zhao, Wei
    Liang, Zhi Xin
    Dai, Yu
    Zhu, Qiang
    Miao, Kai Ling
    Cui, Dong Hua
    Chen, Liang An
    CANCER MEDICINE, 2019, 8 (03): : 910 - 919
  • [37] Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA
    Nick Veltmaat
    Yujie Zhong
    Filipe Montes de Jesus
    Geok Wee Tan
    Johanna A. A. Bult
    Martijn M. Terpstra
    Pim G. N. J. Mutsaers
    Wendy B. C. Stevens
    Rogier Mous
    Joost S. P. Vermaat
    Martine E. D. Chamuleau
    Walter Noordzij
    Erik A. M. Verschuuren
    Klaas Kok
    Joost L. Kluiver
    Arjan Diepstra
    Wouter J. Plattel
    Anke van den Berg
    Marcel Nijland
    Journal of Hematology & Oncology, 16
  • [38] Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA
    Veltmaat, Nick
    Zhong, Yujie
    de Jesus, Filipe Montes
    Tan, Geok Wee
    Bult, Johanna A. A.
    Terpstra, Martijn M.
    Mutsaers, Pim G. N. J.
    Stevens, Wendy B. C.
    Mous, Rogier
    Vermaat, Joost S. P.
    Chamuleau, Martine E. D.
    Noordzij, Walter
    Verschuuren, Erik A. M.
    Kok, Klaas
    Kluiver, Joost L.
    Diepstra, Arjan
    Plattel, Wouter J.
    Van den Berg, Anke
    Nijland, Marcel
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
  • [39] Expanding the landscape of actionable genomic alterations in metastatic breast cancer: comprehensive genomic profiling for all?
    Hilbers, F. S.
    Aftimos, P.
    ANNALS OF ONCOLOGY, 2020, 31 (08) : 967 - 969
  • [40] Comprehensive genomic profiling of matched primary prostate cancer tissue and cell-free DNA (cfDNA) to assess ontogeny of BRCA1/BRCA2 mutations.
    McFarland, Taylor Ryan
    Nussenzveig, Roberto
    Swami, Umang
    Sayegh, Nicolas
    Kessel, Adam
    Sharma, Prayushi
    Li Haoran
    Kohli, Manish
    Maughan, Benjamin Louis
    Pal, Sumanta K.
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)